Targeting major diseases and immunotherapy fields, Amoytop Biotech has built an innovation platform covering the expression, long-acting modification and industrialization of various protein drugs, and owned the innovation ability in fundamental research, pilot-scale research, clinical study and industrialization research. Currently, Amoytop Biotech has established a National Postdoctoral Research Station for Enterprise and a National-Local Joint Engineering Research Center. It is recognized as a National Innovative Enterprise and National IP Advantageous Enterprise. In the future, Amoytop Biotech will continue to focus on immunology and metabolism, prioritizing the advancement of functional cure for hepatitis B. We will maintain substantial investment in scientific research, accelerate the development of new drug, and provide products and services of higher quality for human health through continuous innovation in biotechnology.